Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View

The incidence of melanoma is increasing worldwide and despite early detection and intervention, the number of patients dying from the metastatic disease continues to rise. The prognosis of advanced melanoma remains poor, with a median survival between 6 and 9 months. Over the past 30 years and despite extensive clinical research, the treatment options for metastatic disease were limited, and melanoma is still considered as one of the most therapy-resistant malignancies. Single-agent and combination chemotherapy, hormonal therapy, biochemotherapy, immunotherapy, targeted agent therapy, and combination regimens failed to show significant improvement in overall survival.